Table 1.
Baseline characteristics and treatment details
|
Characteristic
|
Value
|
| No. of patients | 71 |
| Age, yr, median (IQR) | 64.8 (57.1-69.6) |
| Sex, male, n (%) | 41 (57.8) |
| ECOG, 0, n (%) | 61 (85.9) |
| Primary tumour location, n (%) | |
| Head | 44 (62.0) |
| Body | 25 (35.2) |
| Neck | 2 (2.8) |
| Tumour size (mm), median (IQR) | 40 (30-45) |
| Biliary stent, present, n (%) | 25 (35.2) |
| CA19-9 (U/mL) at diagnosis | 951 (± 1134) |
| CA19-9 (U/mL) after chemotherapy (before RAdAR) | 106 (± 160) |
| Clinical T stage1, n (%) | |
| T2 | 6 (8.5) |
| T3 | 11 (15.5) |
| T4 | 54 (76.0) |
| Clinical N stage1, n (%) | |
| N0 | 34 (47.9) |
| N1 | 37 (52.1) |
| Pre-RAdAR chemotherapy regimen, n (%) | |
| FOLFIRINOX | 30 (42.3) |
| Gemcitabine + nab-paclitaxel | 41 (57.7) |
| RAdAR approach, n (%) | |
| SAbR | 59 (83.2) |
| HART | 12 (16.9) |
| Delivery technique, n (%) | |
| RapidArc® Technology | 55 (77.5) |
| TomoTherapy® System | 16 (22.5) |
| Resected patients2, n (%) | 19 (26.8) |
| R status3, n (%) | |
| R0 | 12 (63.2) |
| R1 | 7 (36.8) |
1
Per the AJCC staging system, eighth edition.
2
Exploratory laparotomy in 32 patients (45.1%), resection/exploration ratio 59.4%.
3
Among resected patients, n = 19.
CA: Celiac artery; CHA: Common hepatic artery; FOLFIRINOX: Fluorouracil, leucovorin, oxaliplatin; HART: Hypofractionated ablative radiotherapy; IQR: Interquartile range; PV: Portal vein; SMA: Superior mesenteric artery; SAbR: Stereotactic ablative radiation therapy; SMV: Superior mesenteric vein.